Vavricka, Stephan R; Schoepfer, Alain M; Bansky, Georg; Binek, Janek; Felley, Christian; Geyer, Martin; Manz, Michael; Rogler, Gerhard; de Saussure, Philippe; Sauter, Bernhard; Scharl, Michael; Seibold, Frank; Straumann, Alex; Michetti, Pierre; Swiss, IBDnet (2011). Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflammatory bowel diseases, 17(7), pp. 1530-9. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1002/ibd.21521
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
00054725-201107000-00008.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (322kB) |
Certolizumab pegol (Cimzia, CZP) was approved for the treatment of Crohn's disease (CD) patients in 2007 in Switzerland as the first country worldwide. This prospective phase IV study aimed to evaluate the efficacy and safety of CZP over 26 weeks in a multicenter cohort of practice-based patients.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology |
UniBE Contributor: |
Seibold, Frank Werner |
ISSN: |
1078-0998 |
Publisher: |
Lippincott Williams & Wilkins |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:22 |
Last Modified: |
21 Dec 2022 15:34 |
Publisher DOI: |
10.1002/ibd.21521 |
PubMed ID: |
21674709 |
Web of Science ID: |
000292415200008 |
BORIS DOI: |
10.48350/7747 |
URI: |
https://boris.unibe.ch/id/eprint/7747 (FactScience: 213073) |
Actions (login required)
 |
Edit item |